Texte AlternatifThe transaction enhances Aptar Pharma’s ability to transform ideas into user-centric solutions by capturing the voice of the patient every step of the way, from formulation to device design capabilities, and bring best-in-class drug delivery solutions to market.

Founded in 1991, Metaphase incorporates various areas of specialization in their User Centered Design Innovation Process, combining them with extensive expertise in Industrial Design and Human Factors research and support. These include formative and summative studies, threshold analysis, patient journey mapping, risk analysis, regulatory submission support and UX design to help their clients optimize their product development journey.

Metaphase will be integrated into Noble, an Aptar Pharma company and a world leader in drug delivery training device programs, medical device training solutions, market insight services and patient onboarding strategies. The addition of Metaphase to Noble enhances Aptar Pharma’s patient-centric approach. Metaphase’s expertise will also compliment the products and services that Noble currently provides to pharmaceutical and biotech companies to help improve patient training and onboarding, including their Human Factors Plus (HF+) program. Launched in 2021, Noble’s HF+ program offers their clients an expansive platform of services including device selection, product design solutions, human factors testing, risk analysis, packaging and labeling services, and regulatory submission support.

“The combined expertise of Noble and Metaphase in Human Factors fully aligns with our mission to bring the voice of the patient into all parts of the development process. At Aptar Pharma, our primary goal is improving patients’ experiences and health outcomes,” comments Gael Touya (picture), President of Aptar Pharma.

All rights reserved except agreement written by Emballage Digest or mention of the magazine